<DOC>
	<DOCNO>NCT00472056</DOCNO>
	<brief_summary>Cohort 1 : Patients less equal 65 year age . 1 . To determine disease-free survival ( DFS ) 2 arm ( standard dose versus high dose rituximab ) Cohort 2 : Patients older 65 year age 1 . To determine disease-free survival ( DFS ) 2 arm ( standard dose versus high dose rituximab ) 2 . To determine treatment related mortality ( TRM )</brief_summary>
	<brief_title>Rituximab Addition Autologous Transplantation With BEAM Patients With Lymphoid Malignancies</brief_title>
	<detailed_description>Carmustine , cytarabine , etoposide , melphalan , rituximab standard chemotherapy drug . If find eligible take part study , randomly assign ( toss coin ) one two treatment group . Participants one group receive high dose rituximab transplantation high dose chemotherapy . Participants group receive standard dose rituximab transplantation high dose chemotherapy . The first 10 patient enrol study equal chance assign either group . After first 10 participant enrol , remain participant high chance assign group proven effective . All participant plastic tube ( catheter ) insert collarbone . This catheter leave place entire treatment period . The catheter use deliver drug collection transfusion stem cell . When possible , drug need give vein give use catheter . Stem cell collection do separate study patient take part study stem cell collection complete . You adequate number stem cell collect store eligible high-dose chemotherapy transplantation . All treatment give M. D. Anderson . You admit hospital receive high dose chemotherapy stay hospital 3-4 week . You give carmustine vein 1 hour Day 1 . On Days 2 - 5 , give cytarabine vein 1 hour etoposide vein 3 hour . This repeat every 12 hour Days 2-5 . On Day 6 , give melphalan vein 30 minute . On Day 7 , stem cell collect earlier give back ( `` transplant '' ) catheter 30-45 minute . You also receive either high dose standard dose rituximab vein 4-6 hour one day transplant ( Day 1 ) 1 week later ( Day 8 ) . You receive G-CSF injection star Day 1 ( one day transplant stem cell infusion ) . These continue cell count reach appropriate level least 3 day row . Blood test ( 2 teaspoon ) do every day hospital track effect transplant . You ask return M. D. Anderson 3 month 6 month transplantation , every 6 month 3 year , year 5 year transplant date . At visit get blood work ( 1-2 tablespoon ) , CT scan , test like bone marrow ( need ) determine status lymphoma . This investigational study . All drug use study FDA approve commercially available . Up 100 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients histologically proven diffuse large Bcell ( CD20 positive ) transform follicular nonHodgkin 's lymphoma , relapse conventional chemotherapy eligible protocol high priority 2 . Patients must chemosensitive disease salvage chemotherapy le 5 % bone marrow involvement lymphoma gross pathologic examination 3 . Age less equal 80 year . There low age limit study . 4 . Zubrod performance status less 2 5 . Negative pregnancy test patient child bear potential 6 . Must willing sign inform consent 7 . Should seronegative HIV , hepatitis B surface antigen , hepatitis C antibody . 1 . Patients know active CNS disease exclude . Patients prior history CNS disease negative MRI brain ( and/or spine indicate ) negative CSF cytology within 4 week enrollment study . 2 . Less 3 week last cytotoxic chemotherapy 3 . Serum bilirubin &gt; 1.5 mg/dl 4 . Serum transaminases &gt; 2X/ULN 5 . Serum creatinine &gt; 1.6 mg/dl 6 . Failure collect 3 x 1,000,000 CD34+ stem cells/kg body weight 7 . Left ventricular ejection fraction &lt; 40 % , unless clear cardiology 8 . Corrected DLCO &lt; 50 % 9 . Patients anticoagulant antiplatelet agent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>BEAM Chemotherapy</keyword>
	<keyword>Carmustine</keyword>
	<keyword>BCNU</keyword>
	<keyword>BiCNU</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>